DecisionDx-Melanoma

Listen to how DecisionDx-Melanoma helps Dr. Brook Brouha impact his patient's care!

Did you know? Prolonged exposure to UV radiation is a major risk factor for developing #SkinCancer, including #melanoma, the most dangerous form. Always #PracticeSafeSun: cover up, seek shade, and wear sunscreen, but don't forget to regularly check your skin. Monitor spots and moles: if they have one or more of the ABCDEs, see your dermatologist. #UVSafetyAwarenessMonth #ShareTheFacts #CastleCares

June is National #CancerSuvivorsMonth. We celebrate Morgan England, a stage III melanoma survivor, who advocated to take the DecisionDx-Melanoma test, the results of which she says continue to help reduce her anxiety and provide confidence about her future. https://hubs.la/Q02DsW4W0 DecisionDx-Melanoma is Castle's gene expression profile (GEP) test that analyzes a patient's unique tumor biology to predict their personal risk of recurrence and/or metastasis. It can help to improve prognostic accuracy, better inform management decisions, and positively impact outcomes.

June is National #CancerSuvivorsMonth. We celebrate Greg, a father, husband, avid outdoorsman, and #melanoma survivor whose DecisionDx-Melanoma test results helped him move from fear to confidence. "Just seeing those results was a huge relief for me." https://hubs.la/Q02BmZHk0 DecisionDx-Melanoma is Castle's gene expression profile (GEP) test that analyzes a patient's unique tumor biology to predict their personal risk of recurrence and/or metastasis. It can help to improve prognostic accuracy, better inform management decisions, and positively impact outcomes.

Going to the Summer SDPA conference? Make sure to check out the Product Theater session on how to use GEP for personalized patient risk assessment.

#TeamCastle stepped it up beach-style recently for the 18th annual AIM at Melanoma's Steps Against Melanoma in Galveston, Texas. We were so proud to be part of the event, helping raise $10.5K to support #melanoma research. #CastleCares

NEW DATA: Castle will present new data related to its DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 1. Highlights/details: https://hubs.la/Q02z0_1w0 #DecisionDx #ASCO2024 #Melanoma #UvealMelanoma

What can help determine the risk associated with #melanoma? DecisionDx-Melanoma® is a comprehensive gene expression profile (#GEP) test that provides information to help guide risk-aligned management based on a patient's tumor biology, helping patients and providers alike make better, more informed decisions. Learn more at https://hubs.la/Q02xNL5f0. #SkinCancerAwarenessMonth🌞 #MelanomaAwareness #GeneExpressionProfiling #DecisionDx

Don't miss out on the newest #TheBalancingAct episode as we highlight the vital role of early prevention and detection of Squamous Cell Carcinoma with Castle Biosciences, Inc. Managing Squamous Cell Carcinoma is a significant clinical issue as deaths from SCC are now estimated to exceed those from melanoma. DecisionDx-SCC is a gene expression profile test that accurately predicts metastatic risk for patients diagnosed with SCC and one or more risk factors. The test results provide personalized and accurate prognostic information to inform the most appropriate care for patients. Watch the full story at TheBalancingAct.com and learn more at castlebiosciences.com #SquamousCellCarcinoma #CastleBiosciences #DecisionDxSCC #SquamousCellCarcinomaTreatment #SCC #SkinCancer #Melanoma #SccManagement

⏰SET YOUR ALARM⏰ You won't want to miss the latest episode of The Balancing Act showcasing @DecisionDx-SCC and DecisionDx-Melanoma. Tune in this Monday, May 6th at 7:30 AM EST and 7:30 AM PST to catch the on Lifetime.